These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12177114)

  • 1. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
    J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
    Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
    Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
    Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
    van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
    J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
    Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A
    Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
    Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
    Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
    Kao SC; McCaughan B; Muljono A; Boyer M
    J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
    Kuribayashi K; Voss S; Nishiuma S; Arakawa K; Nogi Y; Mikami K; Kudoh S
    Lung Cancer; 2012 Mar; 75(3):353-9. PubMed ID: 21890228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.